Form 4: Clearside Biomedical Director Clay Thorp Reports Stock Option Grant
SEC Form 4 Filing
Director Clay Thorp reports acquisition of stock options in Clearside Biomedical, Inc.
Summary
- Clay Thorp, a director of Clearside Biomedical, Inc. (CLSD), reported a transaction on June 20, 2024.
- Thorp acquired 45,000 stock options with an exercise price of $1.15.
- The options vest fully on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, contingent upon continuous service.
- Following the transaction, Thorp directly owns 45,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, neither particularly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of stock option transaction |
| 06/20/2025 | Latest date for full vesting of stock options |
| 06/19/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.